Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by WatchLearnEarnon Oct 12, 2018 9:48pm

196 Views

Post# 28793071

RE:RE:RE:RE:Holding Strong for ANTIBE

$4.00/share pre-split SP would certainly bring a lot of peace to my world, so no qualms here!

Jefferam1 wrote: From AGM circular
"to consider and, if deemed advisable, to pass, with or without variation, a special resolution approving an amendment to the articles of incorporation of the Corporation to consolidate its issued and outstanding Common Shares on the basis of a ratio within the range of one post-consolidation Common Share for every five (5) pre-consolidation Common Shares to one post-consolidation Common Share for every ten (10) pre-consolidation Common Shares, with the ratio to be selected and implemented by the Board of Directors in its sole discretion, if at all, at any time prior to May 29, 2019 as more particularly described in the Circular"

So they have till May 29, 2019 to do this.

Reading between the lines, they want to have Phase 2 results being positive to get share price up over $1 (ideally) but minimum over 0.55 so they can do 10:1 reverse split.
This would take it to a $5.50 stock (or approx 4.20 USD) which will meet minimum for NASDAQ listing. Which then in turn can attrack further interest to double stock price prior to actually signing a deal.
If we are over $1 we would likely only do a 5:1

Now that being said, they likely don't hit there number in time as they will likely have results in June 2019 (or my guess a little later).

So what will probably happen is prior to next AGM they will pass the same (or similar vote again).
Then come July 2019 they have fantasic results (Hooray!!!). Prices goes up north of $1, do a 5:1 reverse split. Get listed on Nasdaq, price goes up again as negotiations happen, we are now worth well over $500M market cap. We make a big deal with big Pharam taking us north of 1$ market cap and making it an equilevant of > $20/share ($4/share pre split). and everyone is happy, Kumbaya, and now we have world peace.
ok so maybe I took that a little too far.